PURPOSE: We had previously identified a new transmembrane collagen, type XXIII, in metastatic rat prostate carcinoma cells. The purpose of this study was to determine the expression of collagen XXIII in human prostate cancer and investigate its relationship with disease progression. EXPERIMENTAL DESIGN: We investigated collagen XXIII expression in prostate cancer tissue and did a retrospective analysis of association with prostate-specific antigen (PSA)-defined disease recurrence. The presence of collagen XXIII in prostate cancer patient urine was also assessed before and after prostatectomy. RESULTS: Collagen XXIII protein was detected at very low levels in benign prostate tissue and was significantly increased in prostate cancer. Distant metastases exhibited significantly higher collagen XXIII levels compared with either localized prostate cancer or regional (lymph node) metastases. Patients with high collagen XXIII levels had a 2.8-fold higher risk of PSA failure with median time to failure of 8.1 months, compared with low collagen XXIII patients with a median time to failure of 5 years. Multivariate Cox regression showed that the presence of collagen XXIII was significantly associated with time to PSA recurrence, independent of other clinical variables. Collagen XXIII was also detected in prostate cancer patient urine, with reduced levels after prostatectomy, indicating potential as a noninvasive fluid biomarker. CONCLUSIONS: We present the first report demonstrating increased collagen XXIII expression in prostate cancer tissue. We show that collagen XXIII level is a significant independent predictor of PSA-defined disease recurrence, suggesting a potential role as a molecular biomarker of prostate cancer progression and metastasis.
PURPOSE: We had previously identified a new transmembrane collagen, type XXIII, in metastatic ratprostate carcinoma cells. The purpose of this study was to determine the expression of collagen XXIII in humanprostate cancer and investigate its relationship with disease progression. EXPERIMENTAL DESIGN: We investigated collagen XXIII expression in prostate cancer tissue and did a retrospective analysis of association with prostate-specific antigen (PSA)-defined disease recurrence. The presence of collagen XXIII in prostate cancerpatient urine was also assessed before and after prostatectomy. RESULTS: Collagen XXIII protein was detected at very low levels in benign prostate tissue and was significantly increased in prostate cancer. Distant metastases exhibited significantly higher collagen XXIII levels compared with either localized prostate cancer or regional (lymph node) metastases. Patients with high collagen XXIII levels had a 2.8-fold higher risk of PSA failure with median time to failure of 8.1 months, compared with low collagen XXIII patients with a median time to failure of 5 years. Multivariate Cox regression showed that the presence of collagen XXIII was significantly associated with time to PSA recurrence, independent of other clinical variables. Collagen XXIII was also detected in prostate cancerpatient urine, with reduced levels after prostatectomy, indicating potential as a noninvasive fluid biomarker. CONCLUSIONS: We present the first report demonstrating increased collagen XXIII expression in prostate cancer tissue. We show that collagen XXIII level is a significant independent predictor of PSA-defined disease recurrence, suggesting a potential role as a molecular biomarker of prostate cancer progression and metastasis.
Authors: Kristin A Spivey; Jacqueline Banyard; Luisa M Solis; Ignacio I Wistuba; Justine A Barletta; Leena Gandhi; Henry A Feldman; Scott J Rodig; Lucian R Chirieac; Bruce R Zetter Journal: Cancer Epidemiol Biomarkers Prev Date: 2010-05 Impact factor: 4.254
Authors: Guido Veit; Daniela Zwolanek; Beate Eckes; Stephan Niland; Jarmo Käpylä; Manon C Zweers; Akemi Ishada-Yamamoto; Thomas Krieg; Jyrki Heino; Johannes A Eble; Manuel Koch Journal: J Biol Chem Date: 2011-06-07 Impact factor: 5.157
Authors: Peggi M Angel; Laura Spruill; Melanie Jefferson; Jennifer R Bethard; Lauren E Ball; Chanita Hughes-Halbert; Richard R Drake Journal: Prostate Date: 2020-07-20 Impact factor: 4.104
Authors: Qinghua Xu; Jessica E Torres; Mazin Hakim; Paulina M Babiak; Pallabi Pal; Carly M Battistoni; Michael Nguyen; Alyssa Panitch; Luis Solorio; Julie C Liu Journal: Mater Sci Eng R Rep Date: 2021-07-30 Impact factor: 33.667
Authors: Karen C Halsted; Kara B Bowen; Laura Bond; Sarah E Luman; Cheryl L Jorcyk; William E Fyffe; Joseph D Kronz; Julia T Oxford Journal: Mod Pathol Date: 2008-07-25 Impact factor: 7.842
Authors: Zhi-Qiang Du; Xia Zhao; Natascha Vukasinovic; Fernanda Rodriguez; Archie C Clutter; Max F Rothschild Journal: PLoS One Date: 2009-03-16 Impact factor: 3.240